Metabolic Market Research for the GLP-1 Era and Every Brand That Follows
GLP-1s have reshaped obesity and diabetes prescribing in just a few years. Oral GLP-1s are now approved for obesity, access barriers are blocking clinically preferred treatments, and HCPs are forming preferences weeks before they prescribe. ZoomRx helps pharma teams stay ahead of all of it.
Why Generic Market Research Falls Short in Metabolic
Access barriers are blocking prescriptions your brand team doesn’t know about
Physicians are prescribing GLP-1s and patients are being turned away at the pharmacy. When access friction is this high, your commercial picture is incomplete without access intelligence built into the research.
Pipeline competition is moving faster than HCP awareness
Next-generation incretins and combination therapies are moving through late-stage trials, and HCP awareness rarely keeps pace. By the time your brand launches, competitor mechanisms may already own the awareness you need to displace.
HCPs decide before they prescribe and you’re not in the room
In metabolic, HCPs research treatment options weeks before writing a script. By the time your team sees a Rx shift, the mindshare battle is already over. Behavioral signals are the earliest warning system.
Digital reach separates the leaders
In Q3 2025, Eli Lilly alone captured 12.2% of all pharma banner ad impressions ZoomRx tracked, and Zepbound and Mounjaro made up nearly half of Lilly’s total. In metabolic, digital execution separates leaders from the field.
Research That Drives Your Next Decision, Not Just Your Next Report
Every ZoomRx metabolic program is built around the question your brand team is actually trying to answer from pre-launch positioning to in-market access optimization.
Brand Tracking (ATU)
Continuous HCP and patient tracking that goes beyond KPIs to actions — surfacing the shifts in awareness, prescription intent, and treatment satisfaction that tell your team what to do next, not just what happened.
Promotional Effectiveness Tracking (PET)
Pre-Launch & Launch Intelligence
Digital & Media tracking
HCP-Patient Conversations
HIPAA-compliant real-world research capturing what actually happens in diabetes and obesity consultations, including how HCPs navigate access conversations, treatment switching, and patient adherence at the point of care.
Ferma: Conference Coverage
Patient Chart Audits (PCA)
What Makes ZoomRx Different in Metabolic Market Research
ZoomRx’s Digital Tracker measures HCP brand attention across healthcare platforms giving your team a leading indicator that moves weeks ahead of prescription trends, when there’s still time to act.
ZoomRx integrates cost, coverage, and access friction data directly into brand tracking and patient chart research, so your team sees the full commercial picture, not just the prescribing intent.
Every ZoomRx metabolic program is designed around your specific HCPs, your indication, and your competitive context not a syndicated study your competitors are also reading.
Ferma’s conference coverage delivers AI session summaries within 4 hours, so your team gets the commercial signal, not a summary written days later when the competitive window has already shifted.
Pre-launch intelligence, brand tracking, promotional effectiveness, digital media, and patient research managed in one workflow, so nothing is lost between vendors and no context has to be rebuilt mid-campaign.
Explore Other Therapeutic Areas
ZoomRx brings pharma market insights, AI-powered platforms and commercial analytics to every major therapeutic area. Explore our work by TA.
Oncology
HCP brand tracking, promotional effectiveness, manufacturer perception studies, and congress intelligence across 40+ indications.
CNS
Metabolic & GLP-1 Intelligence Published by ZoomRx
Frequently Asked Questions
How does ZoomRx track HCP behavior in metabolic markets beyond traditional Rx data?
ZoomRx’s Digital Tracker measures how long HCPs spend reviewing each brand across healthcare websites and how that attention shifts relative to competitors, a leading indicator that moves before prescribing habits change. ZoomRx tracked Zepbound’s rising attention in Q3 2024, months before its revenue closed the gap with Wegovy in Q1 2025.
Which metabolic indications does ZoomRx research cover?
ZoomRx covers type 2 diabetes, obesity and weight management, cardiovascular metabolic conditions, and MASH/MASLD. Research spans the full prescriber base: endocrinologists, primary care physicians, cardiologists, and obesity medicine specialists, depending on where your brand competes.
How do you choose a metabolic market research partner?
Look for a partner that integrates leading indicators, such as HCP digital attention and access barrier data, with traditional brand tracking in one workflow. ZoomRx does this, and its Digital Tracker flagged Zepbound’s momentum in Q3 2024, months before revenue data confirmed it.